Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

Completed · Phase 1

Conditions studied: Autoimmune Pulmonary Alveolar Proteinosis

In brief

Autoimmune PAP is a rare lung disease affecting less than 5,000 individuals in US with no FDA-approved pharmacologic therapy. Results from "off-label" use in case reports and clinical studies completed outside of the US indicate that inhaled rhGM-CSF may be a safe and effective thera-py for autoimmune PAP. Preliminary clinical trials of inhaled rhGM-CSF in autoimmune PAP patients show promising results, 62%-96% therapeutic response rate without any identifiable drug-related adverse effects in at least 73 autoimmune PAP patients. However, the pharmacokinetics (PK), pharmacodynamics (PD), optimal dose, and treatment duration to maximize efficacy are unknown. The goal is to begin to address these knowledge gaps for inhaled sargramostim for autoimmune PAP patients with a pilot safety and PK/PD study (TPSC-110). TPSC-110, PharmPAP, which is a self-controlled open-label, phase I study to evaluate the safety, PK, and PD of inhaled sargra-mostim in autoimmune PAP patients. These results will impact the field by 1) confirming existing published data, 2) monitoring the local effects of inhaled sargramostim in autoimmune PAP patients, 3) potentially demonstrating a safe starting dose for a later trial to evaluate the therapeutic efficacy of inhaled sargramostim for autoimmune PAP.

Key facts

Study ID

NCT03006146

Run by

Children's Hospital Medical Center, Cincinnati

People needed

10

Starts

2017-07-13

Expected to finish

2021-06-07

Last updated by the study team

2021-08-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female
• Age ≥ 18 years and ≤ 80 years
• Able to understand and willing to sign a written informed consent document
• Able and willing to use hand held nebulizer
• Able and willing to adhere to study visit schedule and study procedures
• Diagnosis of autoimmune PAP determined by:
• History of a diagnosis of PAP with or without supporting lung histology or BAL/cytology
• and
• Abnormal serum GM-CSF autoantibody test (GMAb ELISA Test)
• and
• Chest CT findings compatible with a diagnosis of autoimmune PAP
• Evidence of impaired GM-CSF signaling demonstrated by an abnormal STAT5 phosphorylation index (STAT5-PI) test measured in heparinized whole blood at the time screening
• A-aDO2 ≥ 15 mm Hg

You may not qualify if…

• Diagnosis of any other PAP-causing disease
• Autoimmune PAP complicated by:
• Severe disease at screening/enrollment (A-aD02<50)
• Clinically significant pulmonary fibrosis
• History of any clinically significant:
• Other lung disease
• Cardiovascular disease
• Disease requiring use of systemic steroids in past year
• Coagulopathy or other hematologic disease
• Active / serious lung or systemic infection
• Persistent or unexplained fever >101oF within 2 months of study
• Use of any immunosuppressive medication within 3-6 months of screening
• Women who are pregnant or plan to become pregnant
• History of active tobacco/e-cig/marijuana use
• Concomitant or recent use of specific medicines

Where it is running

• University of California, Los Angeles — Los Altos, California, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.